Traded Nov 19, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Traded Oct 24, 2025 · Filed Oct 25, 2025
The CEO of ADMA Biologics sold $96K of ADMA Biologics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$96,000
Shares × reported transaction price
79 days after results of Aug 6, 2025, 12 days before results of Nov 5, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.5% | −0.3% | −1.2% |
| 30 days | +22.7% | −0.8% | +23.5% |
| 90 days | +8.7% | +1.1% | +7.6% |
| 180 days | −29.9% | +4.4% | −34.3% |
Past results only. Not a forecast.
Traded Nov 19, 2025 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Adam S Grossman (President and CEO) sold ~$240K of ADMA Biologics, Inc.
Scheduled in advanceAdam S Grossman (President and CEO) sold ~$96K of ADMA Biologics, Inc.
Scheduled in advance